https://doi.org/10.4081/reumatismo.2020.1274
Severe bullous systemic lupus erythematosus successfully treated with low dose rituximab: a case report from sub-Saharan Africa
Submitted: 20 February 2020
Accepted: 29 April 2020
Published: 23 July 2020
Accepted: 29 April 2020
Abstract Views: 882
PDF: 571
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Bullous systemic lupus erythematosus (BSLE) is a blistering skin condition occurring in lupus patients. Although cutaneous manifestations are common in lupus (59-85%), BSLE is rare, affecting <5% of lupus patients with very few reported cases among Africans. Dapsone is effective in mild to moderate cases, but off-label standard-dose rituximab (1,000 mg 2 weeks apart) has led to good outcomes in refractory cases. We report the case of a 39-yearold African lady with BSLE, who was successfully treated with low-dose rituximab (500 mg 2 weeks apart), healing her skin lesions at one year post-treatment. Low-dose rituximab may be as effective as standard dosing for the treatment of severe bullous SLE and is recommended in low resource settings.
How to Cite
Akpabio, A., & Otike-Odibi, B. (2020). Severe bullous systemic lupus erythematosus successfully treated with low dose rituximab: a case report from sub-Saharan Africa. Reumatismo, 72(2), 115–119. https://doi.org/10.4081/reumatismo.2020.1274
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- A. Bortoluzzi, M. Padovan, I. Farina, E. Galuppi, F. De Leonardis, M. Govoni, Therapeutic strategies in severe neuropsychiatric systemic lupus erythematosus: experience from a tertiary referral centre , Reumatismo: Vol. 64 No. 6 (2012)
- F. Dall'Ara, I. Cavazzana, M. Frassi, M. Taraborelli, M. Fredi, F. Franceschini, L. Andreoli, M. Rossi, C. Cattaneo, A. Tincani, P. Airò, Macrophage activation syndrome in adult systemic lupus erythematosus: report of seven adult cases from a single Italian rheumatology center , Reumatismo: Vol. 70 No. 2 (2018)
- A. Fassio, L. Idolazzi, M. Rossini, O. Viapiana, D. Gatti, A case of mandible Paget’s disease of the bone treated with intravenous neridronate , Reumatismo: Vol. 68 No. 3 (2016)
- M. Taraborelli, M.G. Lazzaroni, N. Martinazzi, M. Fredi, I. Cavazzana, F. Franceschini, A. Tincani, The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus , Reumatismo: Vol. 68 No. 3 (2016)
- M. Taraborelli, F. Inverardi, M. Fredi, A. Ceribelli, I. Cavazzana, A. Tincani, F. Franceschini, Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease? , Reumatismo: Vol. 64 No. 5 (2012)
- G. Pasero, P. Marson, Short story of antirheumatic therapy.VIII. The immunodepressants , Reumatismo: Vol. 64 No. 1 (2012)
- C.C. Macía-Villa, I. Sanchez-Lite, J. Medina-Luezas, Slipped capital femoral epiphysis in adults: case report and review of literature , Reumatismo: Vol. 68 No. 1 (2016)
- M. Di Franco, M.P. Guzzo, F.R. Spinelli, F. Atzeni, P. Sarzi-Puttini, F. Conti, C. Iannuccelli, Pain and systemic lupus erythematosus , Reumatismo: Vol. 66 No. 1 (2014)
- S. Casigliani Rabl, A. Della Rossa, P. Pepe, A. D'Ascanio, M. Mosca, A. Di Vita, S. Bombardieri, Long-term cyclic intravenous iloprost in systemic sclerosis: clinical experience from a single center , Reumatismo: Vol. 64 No. 3 (2012)
- N. Belfeki, M. Smiti Khanfir, F. Said, A. Hamzaoui, T. Ben Salem, I. Ben Ghorbel, M. Lamloum, M.H. Houman, Successful treatment of refractory adult onset Still’s disease with rituximab , Reumatismo: Vol. 68 No. 3 (2016)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
You may also start an advanced similarity search for this article.
